Recent advances in the treatment of type II diabetes mellitus

American Family Physician

Volumn 55, Issue 3, 1997, Pages 817-824

  Baliga, Bantwal Suresh ^a   Fonseca, Vivian A ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CIMETIDINE; COTRIMOXAZOLE; DIGOXIN; FUROSEMIDE; METFORMIN; PHENFORMIN; PROCAINAMIDE; QUINIDINE GLUCONATE; RANITIDINE; TRIAMTERENE; TRIMETHOPRIM; VANCOMYCIN;

CORONARY RISK; DIABETES CONTROL; DIABETES MELLITUS; DRUG CONTRAINDICATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; ORAL DRUG ADMINISTRATION; PATHOGENESIS; REVIEW; TREATMENT PLANNING;

ACARBOSE; ALGORITHMS; BLOOD GLUCOSE; DECISION MAKING; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; TRISACCHARIDES;

EID: 0031052739     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
3. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995;44:796-801.
4. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care 1995;18:1113-23.
5. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45.
6. American Diabetes Association. Consensus statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18:1510-8.
7. American Diabetes Association Task Force on Financing Quality Health Care for Persons with Diabetes. Diabetes outpatient education: the evidence of cost savings. Workshop on approaches to third-party reimbursement for diabetes outpatient education. Alexandria, Va.: American Diabetes Association, 1986.
8. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
9. DeFronzo RA, Goodman AM. Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
10. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
11. Crofford OB. Metformin [Editorial]. N Engl J Med 1995;333:588-9.
12. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.
13. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6:472-4.
14. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44(Suppl 3):47-53.
15. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98:443-51.
16. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-7.
17. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
18. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-64.
19. Chaisson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35.
20. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:153-6.